Scott Alan Wright, M.D., F.A.C.C.

Address
115 W. Fifth Street
Tyler, Texas 75701

Telephone: (903) 595-2283

Education

• 1993-1997: University of Texas Medical Branch at Galveston, Galveston, Texas, Doctorate of Medicine
• 1991-1993: University of Texas at Arlington, Arlington, Texas, Master of Computer Science
• 1984-1989: Texas A&M University, College Station, Texas, Bachelor of Science (Major: Bioengineering)

PostGraduate Training

Internal Medicine Residency

• 1997-2000: University of Texas Medical Branch at Galveston, Galveston, Texas

Cardiology Fellowship

• 2000-2003: University of Texas Medical Branch at Galveston, Galveston, Texas

Board Certification

• 2000-2010: American Board of Internal Medicine
• 2004: American Board of Internal Medicine – Cardiovascular Disease
• 2004: Board Certified in Echocardiography
• 2004: Board of Nuclear Cardiology

• 2000: Texas State Board of Medical Examiners #K9950
• 2003: Nuclear Radiation Certification State of Texas #L04800

Work Experience

• 2003-Present: Cardiovascular Associates Of East Texas, PA, Tyler, Texas
• 2001- 2003: Emergency Department, part-time position, University of Texas Medical Branch at Galveston, Galveston, Texas
• 1991-1992: Graduate Teaching Assistant, University of Texas at Arlington, Department of Computer Science, Instructed classes in microprocessors, C and Pascal
• 1989-1991: Biomedical Engineer, Baylor University Medical Center, Dallas, Texas, Project manager for keyboard emulation software, development of pacemaker analyzer.

Hospital Appointments

• 2003-Present: East Texas Medical Center, Tyler, Texas
• 2003-Present: Trinity Mother Frances Hospital, Tyler, Texas
• 2003-Present: Trinity Mother Frances Hospital, Jacksonville, Texas
• 2003-Present: East Texas Medical Center, Jacksonville, Texas

Professional Societies and Other Memberships

• 1992: Tau Beta Pi Engineering Honors Society

• Investigator – RECORD AF – REgistry on Cardiac rhythm disORDers: an international, observational, prospective survey assessing the control of Atrial Fibrillation.
• Co-Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.
• Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.
• Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.
• Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.
• Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.
• Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).
• Co-Investigator – VISION 305 Study - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.
• Co-Investigator - APEX-AMI Study - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.
• Co-Investigator - XIENCE™ V:  Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.
• High Frequency Electrocardiograms versus Standard Electrocardiograms in Acute Coronary Syndromes:  assessing improved sensitivity of HF-EKG in multiple clinical scenarios including adenosine stress testing, percutaneous interventions, risk stratification in emergency departments. Study done in conjunction with NASA.
• Retrospective Analysis of Adenosine Perfusion Studies in Prediction of Coronary Artery Disease:  Comparing results of adenosine perfusion studies with documented coronary anatomy by cardiac catheterization.
• Masters Thesis, Roger S. Walker, Ph.D.   
  University of Texas at Arlington, Department of Computer Science
  Developed high resolution laser measurement system for Texas Highway Department
• Graduate Research Assistant, Roger S. Walker, Ph.D.
  University of Texas at Arlington, Department of Computer Science
  Studied feasibility and software modeling of laser systems.
• Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes Aventix Pharmaceuticals Protocol Number ENO.GMA.301.  IND# 31532
• Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone:  Cordarone I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US 
• Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Assess The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease
• Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial.  A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
• Co-Investigator – A Multicenter, Randomized, Double-blind, Placebo  Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients  with Stable Angina.
• Co-Investigator – Extra Point.  Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System

Honors

• 2002:  Academic Fellowship Award
• 1995: Honors – Internal Medicine Inpatient
• 1995: Honors – Internal Medicine Outpatient
• 1988: Distinguished Student Award in Engineering

Scholarships

• 1996-1997: Stalnaker Scholarship (2 years)